



PRESS RELEASE, September 20, 2019

New treatment concept presented for leading opinion formers at international symposium and disputation

Significant parts of the research that form the basis of SelectImmune Pharma's operations are included in Inès Ambite's doctoral thesis, which will be publicly defended on September 24, 2019. Invited leading international scientists will take part in the event as well as in a scientific symposium in the field at Lund University on September 23. The symposium is open to the public.

The scientific work in the thesis

- Shows that "good" bacteria have a positive impact on body tissue and prepare the ground for a peaceful coexistence between bacterial flora and the host.
- Identifies bacterial molecules, which are responsible for this effect and can be developed into drugs.
- Defines molecular mechanisms that govern the strong immune response in the most seriously ill patients and therapeutic tools for treating them.
- Analyzes the difference between "good" and "bad" bacteria and what is required in order for a bacteria to cause disease.

The thesis will be publicly defended on September 24. The opponent appointed by the faculty is Professor Arturo Zychlinsky, Director of the Department of Cellular Microbiology at the Max Planck Institute in Berlin.

The symposium will be held on September 23, 2019, starting at 2:00 p.m. in Segerfalkssalen at Lund University and is open to the public. Invited speakers at the symposium on September 23 are, in addition to Professor Zychlinsky, Dr. Molly Ingersoll from the Institut Pasteur in Paris, Professor Thomas Miethke, University of Heidelberg and Professor Ulrich Dobrindt from the University of Münster. Experts from Lund will also take part.

For more information, contact:

Catharina Svanborg

Chairman of the Board, SelectImmune

Pharma AB, Telephone +46 709 42 65 49

E-mail: Catharina.Svanborg@med.lu.se

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The Company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.